Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study).
Journal
Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
10
08
2021
revised:
08
02
2022
accepted:
08
03
2022
pubmed:
26
3
2022
medline:
27
4
2022
entrez:
25
3
2022
Statut:
ppublish
Résumé
Radiotherapy-induced toxicity may negatively impact health-related quality of life (HRQoL). This report investigates the impact of curative-intent radiotherapy on HRQoL and toxicity in early stage and locally-advanced non-small cell lung cancer patients treated with radiotherapy or chemo-radiotherapy enrolled in the observational prospective REQUITE study. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire up to 2 years post radiotherapy. Eleven toxicities were scored by clinicians using the Common Terminology Criteria for Adverse Events (CTCAE) version 4. Toxicity scores were calculated by subtracting baseline values. Mixed model analyses were applied to determine statistical significance (p ≤ 0.01). Meaningful clinical important differences (MCID) were determined for changes in HRQoL. Analysis was performed on the overall data, different radiotherapy techniques, multimodality treatments and disease stages. Data of 510 patients were analysed. There was no significant change in HRQoL or its domains, except for deterioration in cognitive functioning (p = 0.01). Radiotherapy technique had no significant impact on HRQoL. The addition of chemotherapy was significantly associated with HRQoL over time (p <.001). Overall toxicity did not significantly change over time. Acute toxicities of radiation-dermatitis (p =.003), dysphagia (p =.002) and esophagitis (p <.001) peaked at 3 months and decreased thereafter. Pneumonitis initially deteriorated but improved significantly after 12 months (p =.011). A proportion of patients experienced meaningful clinically important improvements and deteriorations in overall HRQoL and its domains. In some patients, pre-treatment symptoms improved gradually. While overall HRQoL and toxicity did not change over time, some patients improved, whereas others experienced acute radiotherapy-induced toxicities and deteriorated HRQoL, especially physical and cognitive functioning. Patient characteristics, more so than radiotherapy technique and treatment modality, impact post-radiotherapy toxicity and HRQoL outcomes. This stresses the importance of considering the potential impact of radiotherapy on individuals' HRQoL, symptoms and toxicity in treatment decision-making.
Identifiants
pubmed: 35334417
pii: S0169-5002(22)00378-6
doi: 10.1016/j.lungcan.2022.03.010
pmc: PMC9698940
mid: NIHMS1834479
pii:
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
228-241Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Références
Radiother Oncol. 2014 Aug;112(2):244-9
pubmed: 25107555
Lancet Oncol. 2020 Feb;21(2):e83-e96
pubmed: 32007209
Perspect Clin Res. 2011 Jul;2(3):84-5
pubmed: 21897881
BMJ Open. 2018 Jan 10;8(1):e019117
pubmed: 29326191
Health Econ Rev. 2013 May 16;3(1):15
pubmed: 23680096
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e291-7
pubmed: 21640503
Br J Radiol. 2015 Jul;88(1051):20150172
pubmed: 26084351
Acta Oncol. 2019 Oct;58(10):1523-1527
pubmed: 31315492
Clin Oncol (R Coll Radiol). 2015 Nov;27(11):679-85
pubmed: 26423636
J Clin Oncol. 1998 Jan;16(1):139-44
pubmed: 9440735
J Man Manip Ther. 2008;16(4):E82-3
pubmed: 19771185
Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):31-7
pubmed: 19864077
Nat Rev Dis Primers. 2019 Feb 21;5(1):13
pubmed: 30792503
Crit Rev Oncol Hematol. 2017 Nov;119:40-49
pubmed: 29065984
Oral Oncol. 2011 Aug;47(8):768-74
pubmed: 21683647
Radiother Oncol. 2013 Jun;107(3):267-73
pubmed: 23759662
Ann Oncol. 2015 Sep;26(9):1846-1858
pubmed: 25888610
Lancet Oncol. 2020 May;21(5):723-732
pubmed: 32213338
J Med Internet Res. 2020 Oct 29;22(10):e19685
pubmed: 33118954
Radiother Oncol. 2019 Sep;138:59-67
pubmed: 31146072
Eur J Cancer. 2014 Nov;50(17):2939-49
pubmed: 25304298
J Thorac Oncol. 2020 Feb;15(2):288-293
pubmed: 31622733
Radiother Oncol. 2016 Dec;121(3):414-419
pubmed: 27637858
J Natl Cancer Inst. 2009 Dec 2;101(23):1624-32
pubmed: 19920223
BMJ. 2013 Jan 28;346:f167
pubmed: 23358487
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
J Natl Cancer Inst. 2017 Sep 1;109(9):
pubmed: 28423407
J Clin Oncol. 2016 Feb 20;34(6):557-65
pubmed: 26644527
J Thorac Dis. 2019 Jan;11(1):154-161
pubmed: 30863584
Ann Oncol. 2004;15 Suppl 4:iv279-82
pubmed: 15477321
Support Care Cancer. 2014 Jan;22(1):79-85
pubmed: 23995815
Clin Lung Cancer. 2016 Sep;17(5):e141-e149
pubmed: 26791542
Acta Oncol. 2018 Nov;57(11):1567-1573
pubmed: 29873277
Eur J Cancer. 2016 Nov;68:73-81
pubmed: 27721057
Cancer. 2015 Dec 15;121(24):4300-23
pubmed: 26451520
Ann Oncol. 2009 Jan;20(1):98-102
pubmed: 18718891
Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):875-90
pubmed: 14529795
J Clin Oncol. 2009 Dec 1;27(34):5816-22
pubmed: 19858383
Radiother Oncol. 2019 Feb;131:166-173
pubmed: 30327236
Radiother Oncol. 2020 Aug;149:94-103
pubmed: 32360828
Front Oncol. 2019 Aug 12;9:715
pubmed: 31456938
Radiother Oncol. 2009 Jun;91(3):443-8
pubmed: 19297049
JAMA Oncol. 2016 Mar;2(3):359-67
pubmed: 26606200
Lung Cancer. 1997 Oct;18(2):119-36
pubmed: 9316004
Ther Adv Med Oncol. 2011 Mar;3(2):57-71
pubmed: 21789156
Eur J Cancer. 1994;30A(5):635-42
pubmed: 8080679
Acta Oncol. 2017 Nov;56(11):1353-1358
pubmed: 28830260
Support Care Cancer. 2015 Dec;23(12):3455-63
pubmed: 25791391
Radiother Oncol. 2018 Feb;126(2):191-197
pubmed: 29229506
Qual Life Res. 2008 Mar;17(2):179-93
pubmed: 18175207
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Radiother Oncol. 2009 Jun;91(3):353-9
pubmed: 19012981
J Clin Oncol. 2016 Sep 20;34(27):3351-2
pubmed: 27432929
J Clin Oncol. 2008 Aug 1;26(22):3770-6
pubmed: 18669465
Lancet Oncol. 2016 Nov;17(11):e510-e514
pubmed: 27769798
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1065-74
pubmed: 21605943